Novartis gains EU nod for vaccine hopeful Bexsero

Novartis ($NVS) nabbed European approval for its new meningitis B vaccine Bexsero, for use in patients 2 months of age and older. The Swiss drugmaker says it's launching the shot as soon as possible across the continent, but country-by-country hurdles remain. Bexsero is seen as Novartis' best hope for breathing new life into its lagging vaccines unit. Release | Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.